New research reveals that the ubiquitin-editing enzyme A20 promotes the degradation of the pro-tumor protein osteopontin in ...

Prioritize viral vectors, oncology and rare disease therapies, with North America offering strong ROI potential through regulatory support, R&D investment and early adoptionDublin, Oct. 08, 2026 ...

A genome-wide screen reveals that the RNA-editing enzyme ADAR1 and the tRNA methyltransferase FTSJ1 actively drive tryptophan ...

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Three exceptional scientists each received $250,000 – the largest unrestricted scientific award available to early-career scientists in the United States – at ...

Scientists at UC San Francisco have developed a way to create cancer-fighting CAR-T cells directly inside the body, potentially avoiding the slow and extremely expensive process of removing, ...

A roundup of six recent studies explores an advanced breast cancer drug combination, atropine for childhood myopia, gene ...

Found in 70 percent of cancers, the gene is seen as a grand orchestrator but has been surprisingly difficult to stop.

Researchers at the Cancer Epigenetics Institute (CEI) at Fox Chase Cancer Center have discovered how to control and stop the ...

Predictions for the 2026 Nobel Prizes in science highlight significant contributions in areas like GLP-1 research and cancer therapies. Carl June is mentioned for his role in developing CAR-T cell ...

Origin Genomics aims to prove the potential benefits of its technology for editing disease-causing genes in human embryos ...

A technique known as prime assembly expands the capabilities of prime editing, allowing larger genome rearrangements and potentially wider clinical applications.